Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to NAV. This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers.
08 Mar 2019
Beating the odds
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Beating the odds
International Biotechnology Trust PLC (IBT:LON) | 653 -13.1 (-0.3%) | Mkt Cap: 248.4m
- Published:
08 Mar 2019 -
Author:
Ed Marten -
Pages:
11
Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to NAV. This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers.